For the first time ever, a drug for COVID-19 designed with artificial intelligence is headed to clinical trials. Insilico Medicine, a Hong Kong-based AI pharmaceutical company, announced last Thursday its ISM3312 therapeutic would be starting clinical trials in China after its preclinical studies found that the drug "significantly reduces" viral load and inflammation in the lungs.